IGF1 and hepatocellular carcinoma: Transwell results also showed that IGF-1 + sorafenib + PPP and IGF-1 + sorafenib + siRNA2 treatment downregulated the migration of HCC cells compared with that of IGF-1 + sorafenib treatment (*p < 0.05) (Fig. 3 C, D).